Bloodstream infection surveillance in a cancer centre: A prospective look at clinical microbiology aspects

Clinical Microbiology and Infection

Volumn 10, Issue 6, 2004, Pages 542-549

  Velasco, E ^a   Byington, R ^a   Martins, C S A ^a   Schirmer, M ^a   Dias, L C M ^a   Goncalves V M S C ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Bacteraemia; Bloodstream infection; Cancer patients; Resistance; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; CANCER CENTER; CENTRAL VENOUS CATHETER; CHILD; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; INDWELLING CATHETER; INFECTION COMPLICATION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NEUTROPENIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SUPERINFECTION; URINARY TRACT INFECTION;

ACINETOBACTER; BACILLI; ENTEROBACTER; ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 3242712275     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00874.x     Document Type: Article

References (40)

1. Weinstein MP, Towns ML, Quartey SM et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
2. Velasco E, Thuler LCS, Martins CAS, Dias LMC, Gonçalves VMS. Risk factors for bloodstream infections at a cancer center. Eur J Clin Microbiol Infect Dis 1998; 17: 587-590.
3. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
4. Velasco E, Thuler LCS, Martins CASM, Dias LMC, Gonçalves VMSC. Prognostic factors in adult cancer patients with a bloodstream infection [abstract P1325]. Clin Microbiol Infect 1997; 3(suppl 2): S328.
5. Jarvis WR, Cookson ST, Robles MB. Prevention of nosocomial bloodstream infections: a national and international priority. Infect Control Hosp Epidemiol 1996; 17: 272-275.
6. Nosocomial Infection National Surveillance Scheme. Surveillance of hospital-acquired bacteraemia in English hospitals 1997-1999. London: PHLS, 2000. http://www.phls.co.uk/publications/index.htm.
7. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33: 289-295.
8. Velasco E, Thuler LCS, Martins CAS, Nucci M, Dias LMC, Gonçalves VMS. Epidemiology of bloodstream infections at a cancer center. São Paulo Med J/Rev Paul Med 2000; 118: 131-138.
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Contr 1988; 16: 128-140.
10. Sickles E, Greene W, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135: 715-719.
11. Miller JM, O'Hara CM. Substrate utilization systems for the identification of bacteria and yeast. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1995; 103-109.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. Wayne, PA: NCCLS, 2000.
13. Lyytikäinen O, Lumio J, Sarkkinen H et al. Nosocomial bloodstream infections in Finnish hospitals during 1999-2002. Clin Infect Dis 2002; 35: e14-19.
14. Byl B, Clevenbergh P, Jacobs F et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29: 60-66.
15. Fluckiger U, Zimmerli W, Sax H, Frei R, Widmer AF. Clinical impact of an infectious diseases service on the management of bloodstream infection. Eur J Clin Microbiol Infect Dis 2000; 19: 493-500.
16. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-494.
17. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 228 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-296.
18. Wenzel RP, Thompson RL, Landry SM, Russell BS, Ponce de Leon S, Miller GB. Hospital-acquired infections in intensive care unit patients: an overview with emphasis on epidemics. Infect Control 1983; 4: 371-375.
19. Taylor GD, Buchanan-Chell M, Kirland T, MacKenzie M, Wiens R. Nosocomial gram-negative bacteremia. Int J Infect Dis 1997; 1: 202-205.
20. D'Agata EMC, Thayer V, Schaffner W. An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect Control Hosp Epidemiol 2000; 21: 588-591.
21. Cantón R, Oliver A, Coque TM, Varela MC, Pérez-Días JC, Baquero F. Epidemiology of extended-spectrum β -lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol 2002; 40: 1237-1243.
22. Lortholary O, Fagon JY, Hoi AB et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20: 790-796.
23. Myllote JM, Mcdermott C. Recurrent gram-negative bacteremia. Am J Med 1988; 85: 159-163.
24. Ehni WF, Reller B, Ellison RT. Bacteremia in granulocytopenic patients in a tertiary-care general hospital. Rev Infect Dis 1991; 13: 613-619.
25. Escande MC, Herbrecht R, French Study Group. Prospective study of bacteremia in cancer patients: results of a French multicentre study. Support Care Cancer 1998; 6: 273-280.
26. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KVI, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer. Arch Intern Med 2000; 160: 501-509.
27. Jugo J, Kennedy R, Crowe MJ et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 2002; 50: 48-55.
28. Cooper GS, Havlir DS, Shlaes DM, Salata RA. Polymicrobial bacteremia in the late 1980s: predictors of outcome and review of the literature. Medicine 1990; 69: 114-123.
29. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in cancer patient. Medicine 1986; 65: 218-225.
30. Martino R, Gómez L, Pericas R et al, Bacteraemia caused by non-glucose-fermenting gram-negative baclli and Aeromonas species in patients with haematological malignancies and solid tumours. Eur J Clin Microbiol Infect Dis 2000; 19: 320-323.
31. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-125.
32. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
33. Karabinis A, Hill C, Leclercq B, Tancrède C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429-432.
34. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
35. Diekeman DJ, Pfaller MA, Jones RN et al. Trends in antimicrobial susceptibility of bacterial isolates from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY participants Group. Int J Antimicrob Agents 2000; 13: 257-271.
36. Rolston KVI, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996; 42: 348-353.
37. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
38. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002; 34: 1600-1606.
39. Fluit AC, Jones ME, Schmitz FJ et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from SENTRY Antimicrobial Surveillance Program, 1997-1998. Clin Infect Dis 2000; 30: 454-460.
40. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis 2001; 7: 188-192.